U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07259161) titled 'Modified Conditioning Regimen for CML-BP' on Sept. 25.
Brief Summary: Study on the Efficacy and Safety of a Reduced-Toxicity Conditioning Regimen Containing Thiotepa and Melphalan in Patients with Blast Phase Chronic Myeloid Leukemia
Study Start Date: Dec. 15
Study Type: INTERVENTIONAL
Condition:
CML,Blast Phase
HSCT
Intervention:
DRUG: Enrolled patients with blast-phase chronic myeloid leukemia received a reduced-toxicity conditioning regimen containing thiotepa, melphalan, and fludarabine prior to undergoing allogeneic hematopoie
This study is a prospective, interventional clinical trial recruiting patients with blast-phase ...